Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia [NA]
This clinical trial investigates whether circulating tumor DNA after six months of treatment can predict outcomes in patients with Waldenstr…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process
This clinical trial is investigating how common neuropathy is in patients with Waldenström macroglobulinemia and aims to describe related pa…
-
CLINICAL_TRIALS other · 2025-09-08Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) [Phase 1, Phase 2]
This clinical trial update indicates that Nemtabrutinib (MK-1026) is being studied for relapsed or refractory hematologic malignancies in a …
-
CLINICAL_TRIALS trial_result · 2025-09-04Clinical Trial Update: Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia [Phase 1]
This update reports results from a Phase 1 trial evaluating pomalidomide in patients with relapsed or refractory Waldenström macroglobulinem…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia [Phase 1]
A Phase 1 trial evaluating APG-2575 as a single agent or in combination with ibrutinib or rituximab in Waldenström macroglobulinemia has com…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas [Phase 1]
Phase 1 clinical trial evaluating autologous CD22-directed CAR-T cells in patients with recurrent or refractory B-cell lymphomas, including …
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program [NA]
This clinical trial update reports a UNC Lineberger Comprehensive Cancer Center study recruiting participants for a personalized supportive …
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
An ongoing clinical trial update describes using phased variant analysis with next-generation sequencing to enable early assessment of lymph…
-
CLINICAL_TRIALS research · 2025-05-29Clinical Trial Update: Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia [NA]
This is an ongoing clinical study evaluating hyperviscosity syndrome in patients with Waldenström macroglobulinemia; the study is currently …
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia [Phase 2]
Phase 2 study evaluating pirtobrutinib in combination with venetoclax for Waldenström macroglobulinemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia [NA]
This clinical trial is evaluating first-line zanubrutinib in combination with bendamustine and rituximab for Waldenström's macroglobulinemia…
-
CLINICAL_TRIALS research · 2025-04-20Clinical Trial Update: Rifaximin in Patients With Monoclonal Gammopathy [Phase 1]
Phase 1 clinical trial evaluating rifaximin in patients with monoclonal gammopathy; status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) [Phase 4]
Phase 4 study of ibrutinib in Chinese participants with relapsed or refractory Waldenström macroglobulinemia has been completed and results …
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia [Phase 2]
Phase 2 trial evaluating carfilzomib in combination with ibrutinib versus ibrutinib alone in Waldenström macroglobulinemia; the study is cur…
-
CLINICAL_TRIALS approval · 2024-12-18Clinical Trial Update: Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
The document notes that pirtobrutinib is approved for marketing in relation to an expanded access program for multiple B-cell cancers, cover…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
A single-arm expanded-access study of zanubrutinib in Waldenström macroglobulinemia is no longer available.
-
CLINICAL_TRIALS withdrawal · 2024-10-03Clinical Trial Update: B-Cell Hematologic Malignancy Vaccination Registry
A clinical trial update indicates that the B-cell hematologic malignancy vaccination registry (NCT02298816) sponsored by Wake Forest Univers…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation [Phase 2]
Phase 2 trial evaluating Zydelig (idelalisib) as maintenance therapy after autologous stem cell transplantation in B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2024-08-28Clinical Trial Update: Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM [Phase 2]
A Phase 2 study evaluating zanubrutinib plus bendamustine-rituximab for newly diagnosed symptomatic Waldenström macroglobulinemia, currently…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 [Phase 1]
This is a Phase 1 study evaluating the combination of mavorixafor and ibrutinib in Waldenström macroglobulinemia patients with MYD88 and CXC…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies [Phase 1]
Phase 1 trial update for CLBR001 and SWI019 in relapsed/refractory B-cell malignancies has completed enrollment in a study targeting multipl…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL [Phase 1, Phase 2]
Mustang Bio's MB-106 study in relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia has been terminated, covering Phase 1…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up update on patients previously treated with Mustang Bio's CAR-T cell investigational product; the trial has been termin…
-
FDA label_change · 2024-06-04FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) to update the product labeling.